Abstract: A particle accelerator system for producing a charged particle beam having pulses of charged particles that have different energy levels from pulse to pulse. The system enables independent adjustment of the RF power delivered to first and second accelerating sections thereof without adjustment of the RF power generated by an RF source. Such independent adjustment enables the RF power provided to the first accelerating section to be maintained at a level appropriate for optimal particle capturing therein and for producing a tightly bunched beam of particles having different energy levels from pulse to pulse, while enabling the RF power provided to the second accelerating section to be varied in order to vary the energy levels of the charged particles of the charged particle beam from pulse to pulse.

Abstract: The invention provides a monitoring device and its method of use for characterizing and evaluating the recreational quality of a ride event, based on velocity, g-forces, and vertical and lateral movement. The device optionally takes measurements for an individual ride event, displays and stores them, and if desired, transmits them to a central server for storage and or dissemination. The device can thereby document experience characteristics and scores for each ride, optionally reflecting personal preferences in the ratings. The stored data may be used for personal or managerial applications.

Abstract: A method of treating emesis with growth hormone secretagogues, particularly ipamorelin.

Abstract: A highly stable aqueous solution having a molecular cluster with dimensions which are small enough to ensure substantial chemical-physical stability thereof for a relatively long time. To prepare the solution a fluid treatment device is used, which comprises at least one chamber (7) and at least one anode (4) and one cathode (3) arranged in the chamber (7). The anode (4) and cathode (3) are at least partly made of a first metallic material. At least one of the at least one cathode (3) and anode (4) comprises a coating of nanoparticles (5) of a second metallic material.

Abstract: The invention relates to systems and methods for modifying the volatility of petroleum prior to ethanol addition. The methods can include (a) providing (i) a supply of gasoline, (ii) an ethanol standard, and (iii) a supply of butane; (b) analyzing the volatility of a sample formed by mixing the gasoline and ethanol standard; (c) calculating from the volatility a ratio of butane that can be blended into the sample without causing the sample to pass the one or more fixed volatility limits; and (d) blending butane from the butane supply with gasoline from the gasoline supply at or below the ratio calculated in step (c).

Abstract: Methods and formulations are provided for treating migraine and other acute pain episodes using diclofenac, and formulations of diclofenac that provide both rapid and sustained relief from acute pain. Methods and formulations are also provided for treating symptoms that often accompany migraine and acute pain such as photophobia, phonophobia, nausea and vomiting.

Abstract: Provided are rapidly bioavailable solid oral dosage forms of acute pain medications, and moisture resistant packaging that enables the formulation of such rapidly bioavailable dosage forms.

Abstract: A cycling vehicle is provided in which a first rear wheel is powered exclusively by a bicycle pedal, and a second rear wheel is powered exclusively by an electric motor. The cycling vehicle includes bicycle suspension comprising a seat tube, a paired rear triangle with a connecting member that connects the chain stay and the seat stay, a shock absorber in connection with the seat tube and the connecting member, and a pivot arm in connection with the seat tube and the connecting member.

Abstract: The use of additives to stabilize DHA when compressed into tablets, or filled as a powder into capsules, for oral administration.

Abstract: A device and composition for delivering menthol, camphor, eucalyptus essential oils, and other essential oils with balsamic benefits, to be used for the relief of symptoms of common cold.

Abstract: The present invention provides a method of stimulating the motility of the gastrointestinal system in a subject in need thereof, wherein the subject suffers from maladies (i.e., disorders, diseases, conditions, or drug- or surgery-induced dysfunction) of the gastrointestinal system, by administering to the subject a ghrelin mimetic, or pharmaceutically acceptable salt thereof. The invention also provides a method of treating a gastrointestinal malady by co-administering a ghrelin mimetic with a laxative, a H2 receptor antagonist, a serotonin receptor agonist, pure or mixed, an antacid, an opioid antagonist, a proton pump inhibitor, a motilin receptor agonist, dopamine antagonist, a cholinergic agonist, a cholinesterase inhibitor, somatostatin, octreotide, or any combination thereof.

Abstract: The present invention relates to a method of stimulating the motility of the gastrointestinal system in a subject in need thereof, wherein the subject suffers from maladies (i.e., disorders or diseases) of the gastrointestinal system. The method comprises administering to a subject in need thereof a therapeutically effective amount of a growth hormone secretagogue compound or a pharmaceutically acceptable salt, hydrate or solvate thereof. The growth hormone secretagogue can be co-administered with a laxative, a H2 receptor antagonist, a serotonin 5-HT4 agonist, an antacid, an opioid antagonist, a proton pump inhibitor, a motilin receptor agonist, dopamine antagonist, a cholinergic agonist, a cholinesterase inhibitor, somatostatin, octreotide, or any combination thereof.

Abstract: Compounds that are ligands for the growth hormone secretagogue receptor type 1A (GHS-R 1A), as well as pharmaceutically acceptable salts of such compounds, are useful for the manufacture of medicaments for the regulation of food intake.

Abstract: The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments.

Abstract: The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments.

Abstract: The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments.

Abstract: Provided are rapidly bioavailable solid oral dosage forms of acute pain medications, and moisture resistant packaging that enables the formulation of such rapidly bioavailable tablet dosage forms. Also provided is packaging that discourages the use of rapidly bioavailable acute pain medications for off-label chronic pain treatment, and that allows such dosage forms to be manufactured and stored for prolonged periods of time.

Abstract: The present invention relates generally to methods for identifying drug side effects by detecting perturbations in organ-specific molecular blood fingerprints. The invention further relates to methods for identifying drug-specific organ-specific molecular blood fingerprints. As such, the present invention provides compositions comprising organ-specific proteins, detection reagents for detecting such proteins, and panels and arrays for determining organ-specific molecular blood fingerprints.